Healthcare / Drug Manufacturers - Specialty & GenericParis
$69.10
-1.40 (-1.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $68.1M · quality 80.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$803M
P/E
14.0x
↓EV/EBITDA
5.1x
↓ROE
9.7%
↑Gross Margin
74.7%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.9%
FCF CAGR
+8.4%
FCF margin
9.8%
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $525.7M · net income $57.4M · FCF $51.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $525.7M | $525.7M | $539.2M | $529.3M | $539.8M |
| Net Income | $57.4M | $57.4M | $58.7M | $55.6M | $48.0M |
| EBITDA | $116.0M | $116.0M | $114.1M | $112.3M | $116.2M |
| EPS | 4.94 | 4.94 | 4.98 | 4.70 | 4.06 |
| Gross Margin | 74.7% | 74.7% | 71.9% | 70.4% | 70.4% |
| Operating Margin | 15.0% | 15.0% | 14.1% | 14.7% | 15.6% |
| Net Margin | 10.9% | 10.9% | 10.9% | 10.5% | 8.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.04 | 0.03 | 0.04 |
| Current Ratio | 3.08 | 3.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $51.3M | $51.3M | $68.1M | $70.4M | $40.4M |
| Returns | |||||
| ROE | 9.7% | 9.7% | 10.2% | 10.5% | 9.9% |
| Valuation | |||||
| P/E | 13.99 | 13.99 | 15.32 | 20.87 | 22.61 |
| EV/EBITDA | 5.15 | 5.15 | 6.27 | 9.18 | 8.69 |
| P/B | 1.36 | 1.36 | 1.56 | 2.20 | 2.24 |
| Growth & Yield | |||||
| Revenue Growth | -2.5% | -2.5% | 1.9% | -1.9% | — |
| EPS Growth | -0.8% | -0.8% | 6.0% | 15.8% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
7.5%
EPS terminal req.
$6.13
Spread vs growth
-8.3%
5Y implied EPS CAGR
8.5%
EPS terminal req.
$7.42
Spread vs growth
-9.3%
10Y implied EPS CAGR
9.2%
EPS terminal req.
$11.95
Spread vs growth
-10.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.5%
Start / end P/E
14.6x → 14.0x
EPS bridge
4.98 → 4.94
Residual
+0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.